Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single and Multiple Doses of AL002 in Healthy Participants and in Participants With Mild to Moderate Alzheimer's Disease

NCT03635047 is registered in ClinicalTrials.gov with Alector Inc. as lead sponsor.

NCT NCT03635047
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03635047 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single and Multiple Doses of AL002 in Healthy Participants and in Participants With Mild to Moderate Alzheimer's Disease
Lead sponsor
Alector Inc.
Phase
Phase 1
Overall status
Completed
Start date
November 12, 2018
Completion date
November 25, 2020
Enrollment
69 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease, healthy